StockNews.AI
GSK
StockNews.AI
189 days

Law Offices of Frank R. Cruz Encourages GSK plc.

1. A class action lawsuit has been filed against GSK over ADR purchases. 2. Investors purchased ADRs from Feb 2020 to Aug 2022 during the Class Period. 3. Deutsche Bank reported potential liabilities for GSK related to Zantac's NDMA exposure. 4. GSK's stock saw significant declines following liability exposure disclosures. 5. The lawsuit claims GSK made misleading statements about Zantac's risks.

5m saved
Insight
Article

FAQ

Why Bearish?

Pending lawsuit may result in significant financial liabilities, potentially impacting investor sentiment negatively.

How important is it?

Investors' losses from the lawsuit could lead to a broader market perception of GSK's credibility.

Why Long Term?

The ongoing legal issues could take years to resolve, affecting GSK's long-term market position.

Related Companies

GSKNYSE:GSK
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased GSK plc. (“GSK” or the “Company”) (NYSE: GSK) American Depositary Receipts (“ADRs”) between February 5, 2020, and August 14, 2022, inclusive (the “Class Period”). GSK investors have until April 7, 2025 to file a lead plaintiff motion. IF YOU SUFFERED A LOSS ON YOUR GSK INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@frankcruzlaw.com, by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com. What Happened? On August 10, 2022, Deutsche Bank reported that it seemed “very possible” that GSK “will incur the risk of some degree of shared liability, with the only real questions being what the magnitude of liability may be” regarding its drug, Zantac, and an interaction with many foods to create the carcinogen, NDMA. While the Company repeatedly claimed that scientific research did not support a correlation between Zantac and cancer, the Deutsche Bank report stated that the total liability could be between $5 billion and $10 billion. On this news, GSK’s stock price fell $4.30, or 10.7%, over two consecutive trading days to close at $35.75 per ADR on August 11, 2022, thereby injuring investors. Then, on August 15, 2022, GSK disclosed that its liability exposure was between $1 billion and $10 billion and analysts predicted “total exposure low billions to multiple 10s.” On this news, GSK’s stock price fell $1.08, or 3%, to close at $34.95 per ADR on August 15, 2022, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) GSK was fully aware of the source of NDMA and had been for nearly 40 years before withdrawing Zantac from the market; (2) while Defendants asserted that “data published prior to 2019 claims” failed to establish a link between Zantac and cancer, they failed to disclose that GSK possessed unpublished data – the Tanner Report – that did exactly that; (3) the representations about Defendants’ ability to “quantify or reliably estimate the liability” deceived investors, who did not know that GSK had for decades concealed an internal study that implicated the Company’s liability to Zantac users; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired GSK ADRs during the Class Period, you may move the Court no later than April 7, 2025 to request appointment as lead plaintiff in this putative class action lawsuit. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us at: Law Offices of Frank R. Cruz 212 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: info@frankcruzlaw.com Visit our website at: www.frankcruzlaw.com This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Related News